Protein (1)
Launched (1)
Escherichia phage T4 (1)
His Tag (1)
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
Escherichia phage T4 | E. coli | T4 RNA Ligase 1(10U/ul) |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Itolizumab | T-1-hT; EQ-001; T-1-h; h-T1; Bmab-600 | Approved | Biocon Ltd, Center Of Molecular Immunology, Biotech Pharmaceuticals Co Ltd | Alzumab | India | Plaque psoriasis | Biocon Ltd | 2013-01-01 | Dermatomyositis; Graft vs Host Disease; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Respiratory Distress Syndrome, Adult; Psoriasis; Asthma; Plaque psoriasis | Details |

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호



